---
run_id: halo-evidence-vs-diagnosis-validation-v9-famous-sources-supplied-05
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
model_condition: famous_sources_supplied
run_number: 5
model_name: gemma-4-31b-it-mlx
model_id: gemma-4-31b-it-mlx
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
max_tokens: 1024
seed: 502
prompt_source: condition packet (famous_sources_supplied) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a name-level list of famous source titles and authors, then the frozen Advisor prompt; no claims, summaries, source cards, or tension card - see run-packet.md
source_packet_sha256: d057ad83d3f7bf7e5568fa060310fc46d54ebd76e09ae17c88d4f64128eb21dd
condition_packet_sha256: d057ad83d3f7bf7e5568fa060310fc46d54ebd76e09ae17c88d4f64128eb21dd
output_file: model-outputs/famous_sources_supplied-05.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - famous_sources_supplied (run 05)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v9-v1`, condition `famous_sources_supplied`, run 5 of 8. Real local-model run: `gemma-4-31b-it-mlx` via lmstudio, seed 502, on the frozen condition packet.

## Output

**Recommendation:** Run the Claim File Review.

**Why:**
The current "strong quarter" is a classic example of the Halo Effect: executive leadership is attributing financial success to product-market fit (DraftPath) when the evidence suggests it is actually driven by pricing incentives (bundle discounts) and sales narratives (roadmap pitches).

The quantitative data is deceptive. Usage is up, but the behavior is skewed toward managers performing "audit" tasks rather than adjusters performing "workflow" tasks. Furthermore, the critical failure in the health-liability segment—the inability to explain recommendations to reviewers—suggests a fundamental gap in product utility (explainability) that no amount of "enablement" or "event tracking" will fix.

The Claim File Review is the only proposal that addresses the *ground truth* of the value proposition. By inspecting whether suggestions are accepted, overridden, or impossible to explain, you move from "proxy metrics" (usage/bookings) to "value metrics" (utility). This provides the necessary evidence to determine if DraftPath is a scalable product or a sales tool that has reached its ceiling.

**The strongest reason against it:**
It is the slowest and most labor-intensive of the validation tests. Unlike the Usage Quality Sprint (which is automated) or the Commercial Cleanroom (which leverages existing sales motions), a file review requires manual qualitative analysis. With the board locking the budget in twelve days, this method provides a "deep dive" into a small sample rather than a "wide view" of the entire install base, risking a conclusion based on an unrepresentative set of files.

**Observable evidence that would change my mind:**
If the "Commercial Cleanroom" results were to show that renewal rates and expansion intent remained identical between the group receiving the DraftPath pitch and the control group, it would prove that the product's perceived value is currently zero. In that case, I would shift the recommendation to "narrow the company plan around regulated health-liability workflows," as it would signal that the general B2B workflow is not a viable lever and only a highly specialized, compliant solution could save the product.
